Cost and Access Barriers Are Pushing Many GLP-1 Users Off Script
Health Tech·November 14, 2026

A growing number of Americans who take GLP-1 medications such as semaglutide and tirzepatide are not following their prescriptions as written. The reasons described in the reporting come down mostly to money and access, not a lack of interest in treatment.
Patients facing high out-of-pocket costs, coverage denials, or pharmacies that cannot keep the drugs in stock have found their own workarounds. Some stretch a supply by taking smaller doses than prescribed or spacing injections further apart. Others split pens or switch to cheaper options without a clinician involved. Those changes can alter how well the medication controls blood sugar or weight, and they can leave people exposed to side effects their care team never planned for.
A second route runs through unapproved versions of the drugs. Compounded and imported products have filled the gap left by shortages and high list prices. They are sold through online storefronts, med spas, and telehealth services of very uneven quality. Regulators have warned that these products may differ from approved medicines in strength, purity, or sterility, and patients often have no reliable way to check what is in a vial.
The trend matters for more than individual patients. Trial results for these drugs assume people take them as directed, so real-world dosing gaps can make outcomes look worse than the clinical data suggest. It also strengthens the case that coverage rules, pricing, and supply planning shape health results as much as the drugs themselves. Pressure is likely to build on insurers and employers to widen coverage, and on manufacturers to expand lower-cost cash programs. How quickly that happens, and whether it closes the gap, is still an open question.
Reporting based on an external source.